Which company does Pirfenidone/Axri come from?

Pirfenidone/Pirfenidone is developed and produced by Genentech Pharmaceuticals. Founded in 1976, Genentech is one of the pioneers in the field of biopharmaceuticals, focusing on the development of biopharmaceuticals for a variety of diseases including cancer and autoimmune diseases. The company was acquired by Roche in 2009 but remains committed to the development of innovative drugs.

Pirfenidone, as an anti-fibrotic drug, is mainly used to treat idiopathic pulmonary fibrosis (IPF). The disease is a severe interstitial lung disease in which fibrosis gradually develops in patients' lungs, causing breathing difficulties and a reduced quality of life. By inhibiting the production of cytokines and regulating the activity of fibroblasts, pirfenidone can effectively slow down the progression of the disease, prolong the survival of patients, and improve their quality of life.

The drug was approved by the U.S. Food and Drug Administration (FDA) in 2014, becoming one of the first oral drugs approved for the treatment of idiopathic pulmonary fibrosis. After approval, pirfenidone quickly entered the market and was promoted worldwide. Its efficacy and safety have been verified by multiple clinical trials, showing significant clinical benefits.

In addition to the United States, pirfenidone has also been approved in many countries and regions, including China, the European Union, Japan, etc., and has become an important treatment option for patients with idiopathic pulmonary fibrosis around the world. Due to the inhibitory effect of pirfenidone on pulmonary fibrosis, its research in related fields continues to explore its potential application in other lung diseases or fibrosis-related diseases.

When treated with pirfenidone, patients usually need to undergo regular health monitoring based on their doctor's advice to evaluate the effects and side effects of the drug. Although the drug is relatively safe, some side effects may occur, such as gastrointestinal upset, rash, and fatigue. Therefore, patients should pay close attention to their own conditions during medication and provide timely feedback to their doctors.